| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Total revenue-Product | 0 | 0 | - | |
| Total revenue | 0 | 0 | 7,145 | |
| Selling, general and administrative | 5,201 | 5,940 | 12,815 | |
| Research and development | 14,345 | 48,809 | 8,788 | |
| Restructuring charges | 0 | - | - | |
| Cost of goods sold | 0 | 0 | 760 | |
| Total operating expenses | 19,546 | 54,749 | 22,363 | |
| Loss from operations | -19,546 | -54,749 | -15,218 | |
| Gain on sale of business | -177 | 0 | 87,443 | |
| Foreign exchange loss | 0 | -3 | - | |
| Other income | 127 | 158 | - | |
| Interest income | 1,850 | 1,979 | 791 | |
| Interest expense | 0 | 0 | - | |
| Total other income (expense), net | 1,800 | 2,134 | 88,234 | |
| Net (loss) income | -17,746 | -52,615 | 73,016 | |
| Unrealized loss on investments, net of tax | - | - | -15 | |
| Unrealized gain (loss) on investments, net of tax | 130 | 8 | - | |
| Comprehensive (loss) income | -17,616 | -52,607 | 73,001 | |
| Earnings per share, basic | -0.26 | -0.76 | 1.84 | |
| Earnings per share, diluted | -0.26 | -0.76 | 1.83 | |
| Weighted average number of shares outstanding, basic | 69,204,899 | 69,083,127 | 39,640,826 | |
| Weighted average number of shares outstanding, diluted | 69,204,899 | 69,083,127 | 39,932,539 | |
Whitehawk Therapeutics, Inc. (WHWK)
Whitehawk Therapeutics, Inc. (WHWK)